Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
KMT2Ar: early-phase trial registry
2 of 2 indexed KMT2Ar trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
KMT2Ar: 2 US clinical trials tracked, 2 recruiting.
KMT2Ar is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Kura Oncology, running 2 of these trials.
Enrollment posture brief
Registry condition kmt2ar
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
KMT2Ar lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for KMT2Ar on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
KMT2Ar is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology
NCT05735184
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology
NCT06001788
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on KMT2Ar records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on KMT2Ar trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this KMT2Ar page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 KMT2Ar trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kura Oncology sponsors the most KMT2Ar trials on record, review their full trial history before evaluating a specific study. See Kura Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This KMT2Ar condition card totals 2 registered trials; most-linked intervention Ziftomenib; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.